Keep pulling the thread on Richard Smithner.
The speaker believes gene editing and gene writing technologies, such as those being developed by Tessera Therapeutics, will become foundational capabilities in medicine over time.
The speaker sees high potential for CAR-T cell therapies to be used in immunological and autoimmune diseases, expanding beyond their current applications in oncology.
The speaker believes that in vivo CAR-T approaches could dramatically improve the scalability and accessibility of cell therapy.
The speaker highlighted Richard Smithner's ITK program at Corvus as a continuation of the innovative approach from the Imbruvica program.
The speaker predicts that no single therapeutic modality will dominate industry conversations in the current year in the same way that GLP-1 agonists did previously.
The speaker predicts the J.P. Morgan Healthcare Conference will be characterized by clinical validation of new mechanisms of action rather than by hype cycles.
The speaker described recent data from Kymera Therapeutics on its STAT6 targeted protein degrader, published in early December, as 'particularly encouraging'.